[HTML][HTML] 6-gingerol ameliorates weight gain and insulin resistance in metabolic syndrome rats by regulating adipocytokines
S Gunawan, E Munika, ET Wulandari, F Ferdinal… - Saudi Pharmaceutical …, 2023 - Elsevier
Metabolic syndrome (MetS) can lead to increase of insulin resistance (IR) and visceral
adipose tissue production of adipocytokines. 6-gingerol is known to have antioxidant and …
adipose tissue production of adipocytokines. 6-gingerol is known to have antioxidant and …
Milk Exosome–Liposome Hybrid Vesicles with Self-Adapting Surface Properties Overcome the Sequential Absorption Barriers for Oral Delivery of Peptides
P Xiao, H Wang, H Liu, H Yuan, C Guo, Y Feng, P Qi… - ACS …, 2024 - ACS Publications
Milk exosomes (mExos) have demonstrated significant promise as vehicles for the oral
administration of protein and peptide drugs owing to their superior capacity to traverse …
administration of protein and peptide drugs owing to their superior capacity to traverse …
Mechanisms of action of incretin receptor based dual-and tri-agonists in pancreatic islets
Simultaneous activation of the incretin G-protein-coupled receptors (GPCRs) via
unimolecular dual-receptor agonists (UDRA) has emerged as a new therapeutic approach …
unimolecular dual-receptor agonists (UDRA) has emerged as a new therapeutic approach …
[HTML][HTML] Dipeptidyl peptidase 4 inhibitors in type 2 diabetes mellitus management: Pharmacophore virtual screening, molecular docking, pharmacokinetic evaluations …
D Istrate, L Crisan - Processes, 2023 - mdpi.com
Dipeptidyl Peptidase 4 (DPP-4) expressed on the surface of many different cells is a
promising target to develop new candidates for Type 2 diabetes mellitus (T2DM) …
promising target to develop new candidates for Type 2 diabetes mellitus (T2DM) …
[HTML][HTML] Semaglutide as a Possible Calmodulin Binder: Ligand-Based Computational Analyses and Relevance to Its Associated Reward and Appetitive Behaviour …
G Floresta, D Arillotta, V Catalani… - Scientia …, 2024 - mdpi.com
Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, has gained considerable
attention as a therapeutic agent for type 2 diabetes mellitus and obesity. Despite its clinical …
attention as a therapeutic agent for type 2 diabetes mellitus and obesity. Despite its clinical …
[HTML][HTML] Advances in small-molecule insulin secretagogues for diabetes treatment
J Su, J Xu, S Hu, H Ye, L Xie, S Ouyang - Biomedicine & Pharmacotherapy, 2024 - Elsevier
Diabetes, a metabolic disease caused by abnormally high levels of blood glucose, has a
high prevalence rate worldwide and causes a series of complications, including coronary …
high prevalence rate worldwide and causes a series of complications, including coronary …
[HTML][HTML] Molecular processes involved in the shared pathways between cardiovascular diseases and diabetes
J Tokarek, E Budny, M Saar, K Stańczak… - Biomedicines, 2023 - mdpi.com
Cardiovascular diseases and diabetes mellitus are currently among the diseases with the
highest morbidity and mortality. The pathogenesis and development of these diseases …
highest morbidity and mortality. The pathogenesis and development of these diseases …
Dipeptidyl peptidase-4 inhibitors and the risk of gallbladder and bile duct disease among patients with type 2 diabetes: A population-based cohort study
SB Shapiro, H Yin, OHY Yu, L Azoulay - Drug Safety, 2024 - Springer
Introduction The use of dipeptidyl peptidase-4 (DPP-4) inhibitors may be associated with an
increased risk of gallbladder and bile duct disease among patients with type 2 diabetes …
increased risk of gallbladder and bile duct disease among patients with type 2 diabetes …
Therapy of obesity in women with PCOS using GLP-1 analogues—benefits and limitations [Terapia otyłości u kobiet z PCOS przy zastosowaniu analogów GLP-1 …
A Baranowska-Bik - Endokrynologia Polska, 2022 - journals.viamedica.pl
Polycystic ovary syndrome (PCOS) is a heterogeneous endocrine disorder among women of
reproductive age. The incidence ranges from approx. 6% to 20%. PCOS is characterized by …
reproductive age. The incidence ranges from approx. 6% to 20%. PCOS is characterized by …
[HTML][HTML] Anti-inflammatory effects of GLP-1R activation in the retina
A Puddu, D Maggi - International Journal of Molecular Sciences, 2022 - mdpi.com
Glucagon-like peptide-1 (GLP-1) is an incretin hormone, mainly produced by
enteroendocrine L cells, which participates in the regulation of glucose homeostasis, and in …
enteroendocrine L cells, which participates in the regulation of glucose homeostasis, and in …